Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

THOUSAND OAKS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

"Both studies demonstrated that Vectibix administered with chemotherapy significantly improved progression-free survival in patients with wild-type KRAS mCRC," said Marc Peeters, M.D., Ph.D., Professor of Oncology, Antwerp University Hospital and '181' trial lead investigator and study author. "The adverse event profiles in both trials were as expected for an anti-EGFR antibody treatment used in combination with these types of chemotherapy regimens. Additionally, these data reinforce that KRAS status should be known when choosing treatment strategies."

PRIME '203' Results in First-Line mCRC Demonstrate Vectibix Combined with Chemotherapy (FOLFOX) Helped Patients with Wild-type KRAS mCRC Live Longer Without their Disease Worsening (Progression-Free Survival or PFS)

  • The addition of Vectibix to FOLFOX (an oxaliplatin-based chemotherapy) significantly improved PFS (median 9.6 months for Vectibix plus FOLFOX versus 8.0 months for patients treated with FOLFOX alone, hazard ratio 0.80; 95 percent CI: 0.66-0.97; p=0.02) in the first-line treatment of patients with wild-type KRAS mCRC.  
  • Although numerically greater (23.9 months versus 19.7 months, hazard ratio 0.83; 95 percent CI: 0.67-1.02), the improvement in overall survival (OS) (secondary endpoint) in the Vectibix arm did not achieve statistical significance (p=0.072) in the same patient population.
  • Importantly, in patients with tumors harb
    '/>"/>

  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
    2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
    3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
    4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
    5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
    6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
    7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
    8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
    9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
    10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
    11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2015)... Oxford Finance LLC ("Oxford"), a specialty finance ... healthcare services companies, today announced the closing of a ... Inc., a diagnostic testing company focused on improving the ... and improved outcomes.  Proceeds of the loan will be ... of its products in the U.S. and ...
    (Date:4/30/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that it will release first quarter ... after the close of the U.S. financial markets. The ... Thursday, May 7, 2015 at 4:30 p.m. Eastern / ... corporate developments. For both "listen-only" participants and ...
    (Date:4/30/2015)... Rancho Cordova, CA (PRWEB) April 30, 2015 ... today announced that Julie I. Morris has joined SureClinical’s ... Morris is an experienced biotech and technology executive with ... to large Fortune 500 companies. , Ms. Morris ... California-based ag biotech company. She was CFO of MBI ...
    (Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
    Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
    ... Inc., a leading supplier of label-free technology that ... today announced that it has launched two new ... fragment screening, respectively - for use on the ... available via software upgrades and will enable, for ...
    ... - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) ... webcast and conference call of presentations made at an ... Clinical Oncology Annual Meeting (ASCO) on Saturday, May 30, ... , During the reception, OncoGenex management and guest speakers ...
    ... has shown that certain marginalized groups including the ... African Americans and Latinos fare worse than others ... injuries and fatalities. , Now, a ... that they also experience greater terrorism-related fears and make ...
    Cached Biology Technology:ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform 2OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
    (Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
    (Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
    (Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
    Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
    ... June 13, 2012 To spread public knowledge of ... social media app which allows the general public to ... friends. Available free on iTunes ( http://itunes.apple.com/us/app/autism-quiz/id481913653?mt=8 ), ... for Android. Autism Quiz ...
    ... publication this week of a "map" of the bacterial make-up ... the ocean. Microbial communities that live on and in ... to have a critical role in human health and disease. ... ambitious Human Microbiome Project (HMP) to define the boundaries of ...
    ... announces the addition of a significant piece of ... Impact Test System (HITS) recently completed its final ... system is capable of producing horizontal impacts to ... distribution and in-use environments. "With the ...
    Cached Biology News:More than 1 way to be healthy: Map of bacterial makeup of humans reveals microbial rare biosphere 2More than 1 way to be healthy: Map of bacterial makeup of humans reveals microbial rare biosphere 3Westpak Deploys Horizontal Impact Test System (HITS) 2
    ... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
    ... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
    ... provides a fast and simple procedure for concentrating ... exchange, and for removing different types of salts ... spin-column chromatography using Norgens patented protein resin as ... , NaCl, KCl, CaCl 2 , LiCl, and ...
    ... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
    Biology Products: